Real-time enrollment status for this clostridium difficile infection recurrence clinical trial
Current Status
Recruiting
Checked: November 12, 2026 at 9:55 AM UTC
| NCT Number | NCT07513285 |
| Recruiting Status | Recruiting |
| Condition | Clostridium Difficile Infection Recurrence |
| Phase | PHASE2 |
| Target Enrollment | 20 participants |
| Active Locations | 19 sites in the US |
| Sponsor | Acurx Pharmaceuticals Inc. |
| Last Updated on CT.gov | November 9, 2026 (3 days ago) |
As of November 12, 2026: Clinical trial NCT07513285 is currently recruiting participants. This phase2 study for clostridium difficile infection recurrence is actively seeking new participants at 19 locations across the United States. The study is sponsored by Acurx Pharmaceuticals Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07513285 is actively recruiting participants as of November 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 19 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07513285 was last updated 3 days ago (November 9, 2026). HelloStudys verifies this status automatically.